Compare Incyte Corporation (INCY) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Lennar Corporation — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Lennar Corporation trades at $87.46 (market cap $21.05B). The key difference: Incyte Corporation is the larger of the two by market cap, and Lennar Corporation pays a 2.28% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | LEN | |
|---|---|---|
Market Cap | $24.54B | $21.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $142.40 |
52-Week Low | $81.61 | $81.84 |
Enterprise Value | $20.04B | $24.93B |
Dividend Yield | — | 2.28% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
